Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
extensively hydrolyzed casein formula with Lactobacillus rhamnosus GG
- Development stage
- Unknown
- Lead developer
- Mead Johnson Nutrition
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Extensively hydrolyzed casein formula with Lactobacillus rhamnosus GG** is a hypoallergenic oral nutritional formula developed by Mead Johnson for the dietary management of cow's milk allergy in infants and children. It combines extensively hydrolyzed casein, which reduces exposure to intact cow's milk protein allergens, with the probiotic *Lactobacillus rhamnosus* GG. The product is marketed as **Nutramigen LGG** and is used as a non-pharmaceutical therapeutic nutrition intervention rather than a conventional drug. Published clinical and health-economic studies indicate that, compared with extensively hydrolyzed formula without LGG or some alternative hypoallergenic formulas, it can improve symptom control, support earlier acquisition of tolerance to cow's milk protein, and reduce subsequent allergic manifestations, likely through immunomodulatory effects including reduced Th2-skewed inflammation and increased regulatory immune signaling.
- Brand names
- Nutramigen LGG
- Other names
- extensively hydrolyzed casein formula with Lactobacillus rhamnosus GGextensively hydrolyzed casein formula supplemented with Lactobacillus rhamnosus GGextensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG
02
Targets
CSN (Casein)
Beyond the preview
Go deeper on extensively hydrolyzed casein formula with Lactobacillus rhamnosus GG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on extensively hydrolyzed casein formula with Lactobacillus rhamnosus GG.